Q-omics provides the consensus-scored MIR1263 profile across patient tissues and cancer cell-line models. MIR1263 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR1263 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MIR1263 RNA expression shows 11,306 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, KIRC, and STAD as cancer lineages where MIR1263 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1263 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1263 survival associations across molecular data types. MIR1263 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1263 RNA expression–survival associations across cancer types. High MIR1263 expression shows unfavorable associations in UCS, UCEC, BLCA, SKCM, LUSC and LIHC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR1263 RNA expression.
This table summarizes MIR1263 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1263. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1263 shows lower tumor expression in KIRC. The KIRC box plot shows higher MIR1263 RNA expression in normal versus tumor tissue (log2 FC = −0.061, t-test p = .008).
This table shows molecular features associated with MIR1263 in patient tissues and cancer cell lines. In patient samples, MIR1263 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
